These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30369730)

  • 41. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
    Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.
    Ngo JS; Ho MHM
    Can J Hosp Pharm; 2019; 72(4):311-319. PubMed ID: 31452543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
    Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
    J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
    Shukla DK; Gupta D; Aggarwal A; Kumar D
    Indian J Med Paediatr Oncol; 2017; 38(3):360-362. PubMed ID: 29200691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rasburicase: future directions in tumor lysis management.
    Hochberg J; Cairo MS
    Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
    Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S; Lee CS; Ahn S; Sharma A
    J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
    Hossain S; Naber M; Yacobucci MJ
    J Oncol Pharm Pract; 2022 Sep; 28(6):1326-1331. PubMed ID: 34115548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies.
    Azim HA; Bahr SA; Kamal NS; Koura MA; Tolba R; Gad HA; Morsy A; Attia HM; Iskander I; Hammad A; Hemed MF; Abdallah MF; Sadek KA; Taha AH
    Ecancermedicalscience; 2013; 7():378. PubMed ID: 24324529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
    Tatay VS; Castilla JD; Ponce JM; Hurtado JM; Cantero E; Abril ML
    An Pediatr (Barc); 2010 Feb; 72(2):103-10. PubMed ID: 20022572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
    Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
    Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS; Thompson S; Tangirala K; Eaddy MT
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour lysis syndrome in children: experience of last decade.
    Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
    Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
    Teo WY; Loh TF; Tan AM
    Ann Acad Med Singap; 2007 Aug; 36(8):679-83. PubMed ID: 17767339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survey of Anaphylaxis during Rasburicase Re-Administration in Patients with Hematological Malignancies Using a Japanese Claims Database.
    Kobayashi S; Yasu T; Akazawa M
    Curr Oncol; 2022 Dec; 29(12):9826-9832. PubMed ID: 36547186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.